Zentalis Pharmaceuticals Inc (NAS:ZNTL)
$ 10.62 -0.46 (-4.15%) Market Cap: 754.16 Mil Enterprise Value: 307.79 Mil PE Ratio: 0 PB Ratio: 1.64 GF Score: 38/100

Zentalis Pharmaceuticals Inc to Participate in Investor Call Hosted by TD Cowen Transcript

Nov 10, 2023 / 03:00PM GMT
Release Date Price: $9.84 (-1.30%)
Tyler Martin Van Buren
TD Cowen, Research Division - MD & Senior Equity Research Analyst

All right. Looks like it's populating pretty well, and most people are in. So we'll go ahead and get started. Good morning, everyone. Tyler Van Buren here, senior biotech analyst at TD Cowen. Thank you very much for joining us. I know it's been a pretty crazy couple of weeks with earnings and many clinical updates.

One of those important clinical updates was from Zentalis on Monday. And so we thought it would be helpful to have the management team from Zentalis here with us as well as a leading KOL in the space to discuss the updates and provide additional context. So with that, very pleased to have Kim Blackwell, the CEO; Melissa Epperly, the Chief Financial Officer; and Dr. Joyce Liu, who's the Associate Chief and Director of Clinical Research from the Division of Gynecologic Oncology at Dana-Farber.

Before I hand it over to Kim, for those in the audience, please go ahead and e-mail me any questions that you have during the discussion, and I'll do my best to get them asked.

The plan

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot